Tests infliximab in Chinese children with Crohn's disease
Studies infliximab in children aged 6 to 17 with Crohn's disease.
Plain-language title generated from the registry record
Registry title: Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
Source: NCT05906576, who can take part
Where in China
- Beijing Children's Hospital, Capital Medical UniversityBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Trial code
- NCT05906576
- Record updated
- 30 September 2026
- Original description
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.Read full original descriptionShow less
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
Inclusion: Age ranged 6 to 17 years (both inclusive), no gender limitation; A clear diagnosis was made in children with moderate to severe active stage (PCDAI≥30) Crohn's disease refer to the expert consensus on the diagnosis and treatment of inflammatory bowel disease in children (2019 edition); Patients and/or their guardians must sign ICF, and the research agreement/ICF for data collection and data verification shall comply with local laws and regulations; The patient received infliximab for the first time.
Exclusion: Those who accept other anti-TNF-α any biological drugs or any other biologicals; Patients who plan to receive live vaccine within 3 months before signing the informed consent or during the treatment period; Those who have been or being enrolled in other clinical studies within 3 months prior to signing ICF; Patients with contraindications to infliximab use (such as severe infection, active tuberculosis, lymphoma or other malignancies), moderate to severe heart failure, and allergies to other murine proteins, infliximab or any component of this product; The investigator judges the subject inappropriate to be included in this study.